Screener / SEC EDGAR /CIK 0001649904 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Rhythm Pharmaceuticals, Inc. RYTM

Compare with peers Embed
Earnings releases

Latest results release: Nov 3, 2026

8-K item 2.02, exhibit 99

What RYTM's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 3, 2026 · EX-99.1

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business

Open on SEC

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 --

-- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter --

-- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway --

-- Five-year term loan facility secured, providing access to up to $750 million --

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2026.

“Rhythm continues to make strong progress in bringing IMCIVREE ® (setmelanotide) to patients with acquired hypothalamic obesity (HO), highlighted by continued commercial momentum in the United States. Our commercial launch in Japan represents another important milestone in a market with the potential to become our second largest,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals. “The strength of the U.S. launch through two quarters reinforces both the significant unmet need in acquired HO and our opportunity to transform care for patients living with this serious disease.”

Dr. Meeker added, “We are excited about advancing our next-generation MC4R agonists, beginning with bivamelagon. Strong clinical results have reinforced our confidence in its potential across multiple indications, and we look forward to initiating pivotal trials in acquired HO and Prader-Willi syndrome. Our restructured bivamelagon royalty agreement with LG Chem reflects our strong belief in the future potential of the portfolio. With a strong global foundation built on IMCIVREE, bivamelagon entering Phase 3 development and further development planned for RM-718 , there is a clear and compelling path to long- term growth and value creation for Rhythm.”

• Today, the Company announced it has received more than 700 patient start forms for IMCIVREE for acquired HO from more than 500 prescribers as of September 30, 2026, following approval by the U.S. Food and Drug Administration (FDA) on March 19, 2026;

• Revenue from global sales of IMCIVREE was $92.1 million for the third quarter of 2026, an increase of 29% on a sequential basis from the second quarter of 2026. The number of patients on reimbursed therapy globally increased by 20% as compared to the second quarter of 2026.

• U.S.: Revenue of $67.5 million, or 73% of product revenue, was generated in the United States in the third quarter of 2026, an increase of $16.5 million or 32% compared to the second quarter of 2026. The sequential quarter-over- quarter growth in U.S. revenue was driven primarily by increased patient demand for IMCIVREE in acquired HO, as well as continued growth in demand in Bardet-Biedl syndrome (BBS).

• Ex-U.S.: Revenue of $24.7 million, or 27% of product revenue, was generated outside the United States, a sequential increase of $4.4 million or 22% compared to the second quarter of 2026. The number of reimbursed patients on IMCIVREE continued to increase in the third quarter of 2026;

• Today, the Company announced that five presentations have been accepted for presentation at ObesityWeek ® 2026, taking place November 14-17, 2026. Presentations include:

• Definition and Diagnostic Criteria for Acquired Hypothalamic Obesity: Global Expert Consensus;

• Patient-Reported Outcomes From the TRANSCEND Trial in Acquired Hypothalamic Obesity;

• Efficacy and Safety of Setmelanotide in Acquired Hypothalamic Obesity: Final Phase 3 Trial Results;

• Two-Year Phase 3 Trial Results of Setmelanotide in Patients With Acquired Hypothalamic Obesity; and

• Weight Category Improvement Following Setmelanotide in Patients With Acquired Hypothalamic Obesity.

• On November 2, 2026, the Company announced an amendment to its exclusive license agreement with LG Chem for bivamelagon. Under the terms of the amendment, Rhythm has agreed to pay LG Chem $350 million in fixed payments over four years in order to reduce the low-to-mid single digit royalty in the original agreement to 1% royalty on net product revenue generated by Rhythm’s MC4R portfolio;

• On November 2, 2026, the Company entered into a five-year term loan facility led by KKR's HealthCare Royalty ("Healthcare Royalty") in partnership with Blackstone Life Sciences, providing access to up to $750 million of capital. In connection with entry into this loan facility the Company entered into an amended and restated Revenue Interest Financing Agreement with Health Care Royalty;

• On October 13, 2026, the Company announced the commercial launch of IMCIVREE in Japan for patients with acquired HO;

• On September 22, 2026, the Company announced Health Canada approval of IMCIVREE for weight management in adult and pediatric patients 4 years of age and older with acquired HO;

• On September 10, 2026, the Company announced the presentation of six abstracts, including three oral presentations and three poster presentations, at the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting. Presentations included:

• Real-world data demonstrating reductions in BMI and hunger for up to 18 months in paediatric patients with acquired HO treated with setmelanotide through France's early-access program;

• A Phase 3 post-hoc analysis demonstrating improvements across multiple cardiometabolic risk indices with setmelanotide in paediatric patients with acquired HO;

• Long-term weight outcomes with setmelanotide in paediatric patients with BBS, POMC deficiency and LEPR deficiency; and

• Additional analyses evaluating metabolic syndrome severity and risk in acquired HO and clinical characteristics associated with BBS.

• On August 24, 2026, the Company announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved IMCIVREE for patients with acquired HO in Japan;

• On August 11, 2026, the Company announced that IMCIVREE received expanded Marketing Authorization in the United Kingdom for the treatment of obesity and control of hunger in patients with acquired HO due to hypothalamic injury or impairment;

• Complete enrollment in the Phase 1/2, Part D trial evaluating RM-718 in PWS in the second half of 2026;

• Initiate a pivotal Phase 3 trial evaluating bivamelagon in acquired HO by year-end 2026;

• Begin country-level launches of IMCIVREE for acquired HO in Europe beginning with Germany in 2027; and

• Initiate 6-month hyperphagia study to evaluate bivamelagon in PWS in 2027, pending alignment with the FDA.

Cash Position: As of September 30, 2026 , cash, cash equivalents and short-term investments were approximately $320.9 million , as compared to $388.9 million as of December 31, 2025 . Cash, cash equivalents, and short-term investments as of September 30 do not include the $250 million initial draw on the term loan facility or the $70 million payment due to LG Chem under the terms of the amendment to the licensing agreement for bivamelagon.

Revenue: Net product revenues from global sales of IMCIVREE wer e $92.1 million f or the third quarter of 2026, as compared to $51.3 million for the third quarter of 2025.

R&D Expenses: R&D expenses were $52.5 million in the third quarter of 2026, as compared to $46.0 million in the third quarter of 2025. The year-over-year increase was primarily due to an increase in costs in chemistry, manufacturing, and controls (CMC) activity and clinical trial costs, as well as personnel costs, and costs associated with our achievement of a development milestone for our program focused on developing therapies for congenital hyperinsulinism (CHI).

SG&A Expenses: SG&A expenses were $66.8 million for the third quarter of 2026, as compared to $52.4 million for the third quarter of 2025. The year-over-year increase was primarily due to increased personnel costs, including stock-based compensation, related to expanded business operations.

Other income (expense), net: Other expense, net was $(1.5) million for the third quarter of 2026, as compared to other expense, net of $(0.1) million for the third quarter of 2025. The year-over-year increase in other expense, net was primarily due to less interest income earned in the third quarter of 2026 based on decreasing average cash and short-term investments.

Net Loss attributable to common stockholders: Net loss attributable to common stockholders was $(42.4) million for the third quarter of 2026, or a net loss per basic and diluted share of $(0.61) , as compared to a net loss attributable to common stockholders of $(54.3) million for the third quarter of 2025, or a net loss per basic and diluted share of $(0.82).

Revenue: Net product revenues relating to sales of IMCIVREE were $223.5 million for the nine months ended September 30, 2026, as compared to $137.5 million for the nine months ended September 30, 2025.

R&D Expenses: R&D expenses were $137.6 million for the nine months ended September 30, 2026, as compared to $125.3 million for the nine months ended September 30, 2025. The increase was primarily due to increases in personnel costs partially offset by decreases in chemistry, manufacturing, and controls (CMC) costs for drug formulation and autoinjector development for RM-718 and a decrease in clinical trial costs.

SG&A Expenses: SG&A expenses were $197.8 million for the nine months ended September 30, 2026, as compared to $137.5 million for the nine months ended September 30, 2025. The increase was primarily due to higher personnel costs, marketing and promotion costs related to the U.S. and Japanese launches of IMCIVREE for acquired HO, and market access and commercial service costs related to our expanding international business operations.

Other income (expense), net: Other income (expense), net was $(4.5) million for the nine months ended September 30, 2026, as compared to $(3.6) million for the nine months ended September 30, 2025. The increase was primarily due to a change in fair value of the embedded derivative of our deferred royalty obligation and an increase in net unrealized loss on foreign currency, and a decrease in interest income earned.

Financial Guidance: For the year ending December 31, 2026, Rhythm anticipates approximately $360 million to $380 million in Non-GAAP Operating Expenses. Non- GAAP Operating Expenses are derived from:

Non-GAAP Operating Expenses is defined as GAAP operating expenses excluding stock-based compensation and fixed consideration related to in-licensing and milestone payments (see below under "Non-GAAP Financial Measures" for more details).

Based on its current operating plans, Rhythm expects that its cash, cash equivalents and short-term investments as of September 30, 2026 will be sufficient to fund the Company’s planned operations for at least 24 months.

Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its third quarter 2026 financial results and recent business activities. Participants may register for the conference call here . It i s recommended that participants join the call ten minutes prior to the scheduled start.

A webcast of the call will also be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/ . The archived webcast will be available on Rhythm Pharmaceuticals’ website approximately two hours after the conference call and will be available for 30 days following the call.

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE ® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. The European Commission (EC) has authorized setmelanotide for the treatment of obesity and control of hunger in patients 4 years of age and above with acquired hypothalamic obesity. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.

In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired HO, and in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA- approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.

Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:

• Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign

• Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity

Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.

Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

Depression and Suicidal Ideation: Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.

Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.

Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.

Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.

Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.

Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.

Please see the full Prescribing Information for additional Important Safety Information.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the safety, efficacy, potential benefits of, and clinical design or progress, including enrollment and initiation of our clinical trials and studies, of any of our products or product candidates at any dosage or in any indication, including, setmelanotide, bivamelagon, and RM-718; the use of setmelanotide in patients with acquired HO and the success of our commercial launch; the timing of our country-level launches of IMCIVREE in Europe; our expectations surrounding potential regulatory submissions, progress, or approvals and timing thereof for any of our product candidates; the commercial growth of IMCIVREE; the estimated market size and addressable population for our drug products, including setmelanotide for the treatment of acquired HO and the potential for the market in Japan; the future announcement of data from our ongoing clinical trials, and ongoing enrollment in our clinical trials; existing or future collaboration agreements; the Company’s business strategy and plans; our anticipated financial performance and financial position for any period of time, including our estimated Non-GAAP Operating Expenses for the year ending December 31, 2026; and the sufficiency of our cash, cash equivalents and short- term investments to fund our operations for at least 24 months; and the timing of any of the foregoing. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption “Risk Factors” in Rhythm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this press release or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise.

This press release includes Non-GAAP Operating Expenses, a supplemental measure of our performance that is not required by, or presented in accordance with, U.S. GAAP and should not be considered as an alternative to operating expenses or any other performance measure derived in accordance with GAAP.

We define Non-GAAP Operating Expenses as GAAP operating expenses excluding stock-based compensation and fixed consideration related to in-licensing and milestone payments.

We caution investors that amounts presented in accordance with our definition of Non-GAAP Operating Expenses may not be comparable to similar measures disclosed by our competitors because not all companies and analysts calculate this non- GAAP financial measure in the same manner. We present this non-GAAP financial measure because we consider it to be an important supplemental measure of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations.

Management uses this non-GAAP financial measure for planning purposes, including the preparation of our internal annual operating budget and financial projections; to evaluate the performance and effectiveness of our operational strategies; and to evaluate our capacity to expand our business. This non-GAAP financial measure has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for operating expenses or other financial statement data presented in accordance with GAAP in our consolidated financial statements.

Rhythm has not provided a quantitative reconciliation of forecasted Non-GAAP Operating Expenses to forecasted GAAP operating expenses because the Company is unable, without making unreasonable efforts, to calculate the reconciling item, stock-based compensation expenses, with confidence. This item, which could materially affect the computation of forward-looking GAAP operating expenses, is inherently uncertain and depends on various factors, some of which are outside of Rhythm's control.

Assets Current September December assets: 30,2026 31,2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 39,981 $ 54,301 equivalents Short-term 280,963 334,648 investments Accounts receivable, 39,120 26,081 net Inventory 31,187 25,753 Prepaid expenses and 28,111 26,133 other current assets Total current 419,362 466,916 assets Property and 569 1,104 equipment, net Right-of-use 2,694 3,049 asset Intangible 16,678 5,319 assets, net Restricted 1,281 522 cash Other long-term 2,548 3,286 assets Total assets $ 443,132 $ 480,196 Liabilities, Convertible Preferred Stock and Stockholders’ equity Current liabilities: Accounts $ 10,687 $ 13,947 payable Accrued expenses and 124,721 83,855 other current liabilities Lease 731 650 liability Deferred — 194 revenue Deferred royalty 14,751 7,296 obligation, current Total current 150,890 105,942 liabilities Long-term liabilities: Deferred royalty 87,915 100,886 obligation Lease liability, 2,784 3,342 non-current Total 241,589 210,170 liabilities Commitments and contingencies (Note 14) Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 115,000 and 132,500 shares issued and outstanding at September 30, 113,577 130,957 2026 and December 31, 2025, respectively. Liquidation preference of $116,725 and $132,500 as of September 30, 2026, and December 31, 2025, respectively. Stockholders’ equity: Preferred stock, $0.001 par value: 9,850,000 shares authorized; no shares — — issued and outstanding at September 30, 2026 and December 31, 2025 Common stock, $0.001 par value: 120,000,000 shares authorized; 69,314,825 and 67,205,321 70 67 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively Additional paid-in 1,587,823 1,491,675 capital Accumulated other -1,744 -796 comprehensive loss Accumulated -1,498,183 -1,351,877 deficit Total stockholders’ 87,966 139,069 equity Total liabilities, convertible preferred $ 443,132 $ 480,196 stock and stockholders’ equity

Full text with the tables
                                                                                
  EXHIBIT 99.1                                                                  
                                                                                
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business
                                     Update                                     
                                                                                
   -- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired   
hypothalamic obesity (HO) continues with more than 700 patient start forms as of
                             September 30, 2026 --                              
                                                                                
-- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1
             million, an increase of 29% from the prior quarter --              
                                                                                
-- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway
                                       --                                       
                                                                                
 -- Bivamelagon to advance into pivotal development in Prader-Willi syndrome -- 
                                                                                
         -- Rhythm and LG Chem amend bivamelagon licensing agreement --         
                                                                                
-- Five-year term loan facility secured, providing access to up to $750 million 
                                       --                                       
                                                                                
         -- Management to host conference call today at 8:00 a.m. ET --         
                                                                                
  BOSTON, November 3, 2026 –                                                    
                                                                                
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage
biopharmaceutical company focused on transforming the lives of patients living
with rare neuroendocrine diseases, today reported financial results and provided
a business update for the third quarter ended September 30, 2026.

“Rhythm continues to make strong progress in bringing IMCIVREE ® (setmelanotide)
to patients with acquired hypothalamic obesity (HO), highlighted by continued
commercial momentum in the United States. Our commercial launch in Japan
represents another important milestone in a market with the potential to become
our second largest,” said David Meeker, M.D., Chairman, Chief Executive Officer
and President of Rhythm Pharmaceuticals. “The strength of the U.S. launch
through two quarters reinforces both the significant unmet need in acquired HO
and our opportunity to transform care for patients living with this serious
disease.”

Dr. Meeker added, “We are excited about advancing our next-generation MC4R
agonists, beginning with bivamelagon. Strong clinical results have reinforced
our confidence in its potential across multiple indications, and we look forward
to initiating pivotal trials in acquired HO and Prader-Willi syndrome. Our
restructured bivamelagon royalty agreement with LG Chem reflects our strong
belief in the future potential of the portfolio. With a strong global foundation
built on IMCIVREE, bivamelagon entering Phase 3 development and further
development planned for RM-718 , there is a clear and compelling path to long-
term growth and value creation for Rhythm.”
                                                                                
  Recent Business and Development Highlights                                    
                                                                                
• Today, the Company announced it has received more than 700 patient start forms
for IMCIVREE for acquired HO from more than 500 prescribers as of September 30,
2026, following approval by the U.S. Food and Drug Administration (FDA) on March
19, 2026;

• Revenue from global sales of IMCIVREE was $92.1 million for the third quarter
of 2026, an increase of 29% on a sequential basis from the second quarter of
2026. The number of patients on reimbursed therapy globally increased by 20% as
compared to the second quarter of 2026.

• U.S.: Revenue of $67.5 million, or 73% of product revenue, was generated in
the United States in the third quarter of 2026, an increase of $16.5 million or
32% compared to the second quarter of 2026. The sequential quarter-over- quarter
growth in U.S. revenue was driven primarily by increased patient demand for
IMCIVREE in acquired HO, as well as continued growth in demand in Bardet-Biedl
syndrome (BBS).

• Ex-U.S.: Revenue of $24.7 million, or 27% of product revenue, was generated
outside the United States, a sequential increase of $4.4 million or 22% compared
to the second quarter of 2026. The number of reimbursed patients on IMCIVREE
continued to increase in the third quarter of 2026;

• Today, the Company announced that five presentations have been accepted for
presentation at ObesityWeek ® 2026, taking place November 14-17, 2026.
Presentations include:

• Definition and Diagnostic Criteria for Acquired Hypothalamic Obesity: Global
Expert Consensus;

• Patient-Reported Outcomes From the TRANSCEND Trial in Acquired Hypothalamic
Obesity;

• Efficacy and Safety of Setmelanotide in Acquired Hypothalamic Obesity: Final
Phase 3 Trial Results;

• Two-Year Phase 3 Trial Results of Setmelanotide in Patients With Acquired
Hypothalamic Obesity; and

• Weight Category Improvement Following Setmelanotide in Patients With Acquired
Hypothalamic Obesity.

• On November 2, 2026, the Company announced an amendment to its exclusive
license agreement with LG Chem for bivamelagon. Under the terms of the
amendment, Rhythm has agreed to pay LG Chem $350 million in fixed payments over
four years in order to reduce the low-to-mid single digit royalty in the
original agreement to 1% royalty on net product revenue generated by Rhythm’s
MC4R portfolio;

• On November 2, 2026, the Company entered into a five-year term loan facility
led by KKR's HealthCare Royalty ("Healthcare Royalty") in partnership with
Blackstone Life Sciences, providing access to up to $750 million of capital. In
connection with entry
into this loan facility the Company entered into an amended and restated Revenue
Interest Financing Agreement with Health Care Royalty;

• On October 13, 2026, the Company announced the commercial launch of IMCIVREE
in Japan for patients with acquired HO;

• On September 22, 2026, the Company announced Health Canada approval of
IMCIVREE for weight management in adult and pediatric patients 4 years of age
and older with acquired HO;

• On September 10, 2026, the Company announced the presentation of six
abstracts, including three oral presentations and three poster presentations, at
the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting.
Presentations included:

• Real-world data demonstrating reductions in BMI and hunger for up to 18 months
in paediatric patients with acquired HO treated with setmelanotide through
France's early-access program;

• A Phase 3 post-hoc analysis demonstrating improvements across multiple
cardiometabolic risk indices with setmelanotide in paediatric patients with
acquired HO;

• Long-term weight outcomes with setmelanotide in paediatric patients with BBS,
POMC deficiency and LEPR deficiency; and

• Additional analyses evaluating metabolic syndrome severity and risk in
acquired HO and clinical characteristics associated with BBS.

• On August 24, 2026, the Company announced that Japan’s Ministry of Health,
Labour and Welfare (MHLW) approved IMCIVREE for patients with acquired HO in
Japan;

• On August 17, 2026, the Company announced the appointment of Manher (“AJ”)
Joshi, M.D., as Chief Medical Officer;

• On August 11, 2026, the Company announced that IMCIVREE received expanded
Marketing Authorization in the United Kingdom for the treatment of obesity and
control of hunger in patients with acquired HO due to hypothalamic injury or
impairment;
                                                                                
  Anticipated Upcoming Milestones                                               
                                                                                
Rhythm expects to achieve the following near-term milestones:

• Complete enrollment in the Phase 1/2, Part D trial evaluating RM-718 in PWS in
the second half of 2026;

• Initiate a pivotal Phase 3 trial evaluating bivamelagon in acquired HO by
year-end 2026;

• Complete enrollment in the setmelanotide substudy in congenital HO in 2027;

• Begin country-level launches of IMCIVREE for acquired HO in Europe beginning
with Germany in 2027; and

• Initiate 6-month hyperphagia study to evaluate bivamelagon in PWS in 2027,
pending alignment with the FDA.
                                                                                
  Third Quarter 2026 Financial Results                                          
                                                                                
Cash Position: As of September 30, 2026 , cash, cash equivalents and short-term
investments were approximately $320.9 million , as compared to $388.9 million as
of December 31, 2025 . Cash, cash equivalents, and short-term investments as of
September 30 do not include the $250 million initial draw on the term loan
facility or the $70 million payment due to LG Chem under the terms of the
amendment to the licensing agreement for bivamelagon.

Revenue: Net product revenues from global sales of IMCIVREE wer e $92.1 million
f or the third quarter of 2026, as compared to $51.3 million for the third
quarter of 2025.

R&D Expenses: R&D expenses were $52.5 million in the third quarter of 2026, as
compared to $46.0 million in the third quarter of 2025. The year-over-year
increase was primarily due to an increase in costs in chemistry, manufacturing,
and controls (CMC) activity and clinical trial costs, as well as personnel
costs, and costs associated with our achievement of a development milestone for
our program focused on developing therapies for congenital hyperinsulinism
(CHI).

SG&A Expenses: SG&A expenses were $66.8 million for the third quarter of 2026,
as compared to $52.4 million for the third quarter of 2025. The year-over-year
increase was primarily due to increased personnel costs, including stock-based
compensation, related to expanded business operations.

Other income (expense), net: Other expense, net was $(1.5) million for the third
quarter of 2026, as compared to other expense, net of $(0.1) million for the
third quarter of 2025. The year-over-year increase in other expense, net was
primarily due to less interest income earned in the third quarter of 2026 based
on decreasing average cash and short-term investments.

Net Loss attributable to common stockholders: Net loss attributable to common
stockholders was $(42.4) million for the third quarter of 2026, or a net loss
per basic and diluted share of $(0.61) , as compared to a net loss attributable
to common stockholders of $(54.3) million for the third quarter of 2025, or a
net loss per basic and diluted share of $(0.82).
                                                                                
   Year to Date 2026 Financial Results:                                         
                                                                                
Revenue: Net product revenues relating to sales of IMCIVREE were $223.5 million
for the nine months ended September 30, 2026, as compared to $137.5 million for
the nine months ended September 30, 2025.

R&D Expenses: R&D expenses were $137.6 million for the nine months ended
September 30, 2026, as compared to $125.3 million for the nine months ended
September 30, 2025. The increase was primarily due to increases in personnel
costs partially offset by decreases in chemistry, manufacturing, and controls
(CMC) costs for drug formulation and autoinjector development for RM-718 and a
decrease in clinical trial costs.

SG&A Expenses: SG&A expenses were $197.8 million for the nine months ended
September 30, 2026, as compared to $137.5 million for the nine months ended
September 30, 2025. The increase was primarily due to higher personnel costs,
marketing and promotion costs related to the U.S. and Japanese launches of
IMCIVREE for acquired HO, and market access and commercial service costs related
to our expanding international business operations.

Other income (expense), net: Other income (expense), net was $(4.5) million for
the nine months ended September 30, 2026, as compared to $(3.6) million for the
nine months ended September 30, 2025. The increase was primarily due to a change
in fair value of the embedded derivative of our deferred royalty obligation and
an increase in net unrealized loss on foreign currency, and a decrease in
interest income earned.

Financial Guidance: For the year ending December 31, 2026, Rhythm anticipates
approximately $360 million to $380 million in Non-GAAP Operating Expenses. Non-
GAAP Operating Expenses are derived from:

• GAAP total operating expenses, inclusive of:

o R&D expenses of approximately $165 million to $175 million;

o SG&A expenses of approximately $195 million to $205 million; and

o Excluding stock-based compensation.

Non-GAAP Operating Expenses is defined as GAAP operating expenses excluding
stock-based compensation and fixed consideration related to in-licensing and
milestone payments (see below under "Non-GAAP Financial Measures" for more
details).

Based on its current operating plans, Rhythm expects that its cash, cash
equivalents and short-term investments as of September 30, 2026 will be
sufficient to fund the Company’s planned operations for at least 24 months.
                                                                                
  Conference Call Information                                                   
                                                                                
Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m.
ET today to review its third quarter 2026 financial results and recent business
activities. Participants may register for the conference call here . It i s
recommended that participants join the call ten minutes prior to the scheduled
start.

A webcast of the call will also be available under "Events and Presentations" in
the Investor Relations section of the Rhythm Pharmaceuticals website at
https://ir.rhythmtx.com/ . The archived webcast will be available on Rhythm
Pharmaceuticals’ website approximately two hours after the conference call and
will be available for 30 days following the call.
                                                                                
  About Rhythm Pharmaceuticals                                                  
                                                                                
Rhythm is a commercial-stage biopharmaceutical company committed to transforming
the lives of patients and their families living with rare neuroendocrine
diseases. Rhythm’s lead asset, IMCIVREE ® (setmelanotide), an MC4R agonist
designed to treat hyperphagia and severe obesity, is approved by the U.S. Food
and Drug Administration (FDA) to reduce excess body weight and maintain weight
reduction long term in adult and pediatric patients aged 4 years and older with
acquired hypothalamic obesity, adult and pediatric patients 2 years of age and
older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or
genetically confirmed pro-opiomelanocortin (POMC), including proprotein
convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR)
deficiency. Both the European Commission (EC) and the UK’s Medicines &
Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for
the treatment of obesity and the control of hunger associated with genetically
confirmed BBS or genetically confirmed loss-of-function biallelic POMC,
including PCSK1, deficiency or biallelic LEPR deficiency in adults and children
2 years of age and above. The European Commission (EC) has authorized
setmelanotide for the treatment of obesity and control of hunger in patients 4
years of age and above with acquired hypothalamic obesity. Additionally, Rhythm
is advancing a broad clinical development program for setmelanotide in other
rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718,
and a preclinical suite of small molecules for the treatment of congenital
hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
                                                                                
  Setmelanotide Indication                                                      
                                                                                
In the United States, setmelanotide is indicated to reduce excess body weight
and maintain weight reduction long term in adult and pediatric patients aged 4
years and older with acquired HO, and in adult and pediatric patients aged 2
years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome
(BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin
type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-
approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are
interpreted as pathogenic, likely pathogenic, or of uncertain significance
(VUS).
In the European Union and the United Kingdom, setmelanotide is indicated for the
treatment of obesity and the control of hunger associated with genetically
confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or
biallelic LEPR deficiency in adults and children 2 years of age and above. In
the European Union and the United Kingdom, setmelanotide should be prescribed
and supervised by a physician with expertise in obesity with underlying genetic
etiology.
                                                                                
  Limitations of Use                                                            
                                                                                
Setmelanotide is not indicated for the treatment of patients with the following
conditions as setmelanotide would not be expected to be effective:

• Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or
LEPR variants classified as benign or likely benign

• Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency,
including obesity associated with other genetic syndromes and general
(polygenic) obesity
                                                                                
  Contraindication                                                              
                                                                                
Prior serious hypersensitivity to setmelanotide or any of the excipients in
IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been
reported.
                                                                                
   WARNINGS AND PRECAUTIONS                                                     
                                                                                
Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual
adverse reactions in females have occurred. Inform patients that these events
may occur and instruct patients who have an erection lasting longer than 4 hours
to seek emergency medical attention.

Depression and Suicidal Ideation: Depression, suicidal ideation and depressed
mood have occurred. Monitor patients for new onset or worsening depression or
suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients
experience suicidal thoughts or behaviors, or clinically significant or
persistent depression symptoms occur.

Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g.,
anaphylaxis) have been reported. If suspected, advise patients to promptly seek
medical attention and discontinue IMCIVREE.

Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New
Melanocytic Nevi: Generalized or focal increases in skin pigmentation, darkening
of pre-existing nevi, development of new melanocytic nevi and increase in size
of existing melanocytic
nevi have occurred. Perform a full body skin examination prior to initiation and
periodically during treatment to monitor pre-existing and new pigmented lesions.

Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates
and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or
infants. Serious and fatal adverse reactions including “gasping syndrome” can
occur in neonates and low birth weight infants treated with benzyl alcohol
preserved drugs.
                                                                                
  ADVERSE REACTIONS                                                             
                                                                                
Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation,
injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting,
depression, and spontaneous penile erection.
                                                                                
   USE IN SPECIFIC POPULATIONS                                                  
                                                                                
Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue
IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh
the potential risks to the fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1
(833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . See section
4.8 of the Summary of Product Characteristics for information on reporting
suspected adverse reactions in Europe.

Please see the full Prescribing Information for additional Important Safety
Information.
                                                                                
  Forward-Looking Statements                                                    
                                                                                
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements contained in
this press release that do not relate to matters of historical fact should be
considered forward-looking statements, including, without limitation, statements
regarding the safety, efficacy, potential benefits of, and clinical design or
progress, including enrollment and initiation of our clinical trials and
studies, of any of our products or product candidates at any dosage or in any
indication, including, setmelanotide, bivamelagon, and RM-718; the use of
setmelanotide in patients with acquired HO and the success of our commercial
launch; the timing of our country-level launches of IMCIVREE in Europe; our
expectations surrounding potential regulatory submissions, progress, or
approvals and timing thereof for any of our product candidates; the commercial
growth of IMCIVREE; the estimated market size and addressable population for our
drug products, including setmelanotide for the treatment of acquired HO and the
potential for the market in Japan; the future announcement of data from our
ongoing clinical trials, and ongoing enrollment in our clinical trials; existing
or future collaboration agreements; the Company’s business strategy and plans;
our anticipated financial performance and financial position for any period of
time, including our estimated Non-GAAP Operating Expenses for the year ending
December 31, 2026; and the sufficiency of our cash, cash equivalents and short-
term investments to fund our operations for at least 24 months; and the timing
of any of the foregoing. Statements using words such as “expect”, “anticipate”,
“believe”, “may”, “will” and similar terms are also forward-looking statements.
Such statements are subject to numerous risks and uncertainties, including, but
not limited to, our ability to enroll patients in clinical trials, the design
and outcome of clinical trials, the impact of competition, the ability to
achieve or obtain necessary regulatory approvals, risks associated with data
analysis and reporting, unfavorable pricing regulations, third-party
reimbursement practices or healthcare reform initiatives, risks associated with
the laws and regulations governing our international operations and the costs of
any related compliance programs, our ability to successfully commercialize
setmelanotide, our liquidity and expenses, our ability to retain our key
employees and consultants, and to attract, retain and motivate qualified
personnel, and general economic conditions, and the other important factors,
including those discussed under the caption “Risk Factors” in Rhythm’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2026 and our other
filings with the Securities and Exchange Commission. Except as required by law,
we undertake no obligations to make any revisions to the forward-looking
statements contained in this press release or to update them to reflect events
or circumstances occurring after the date of this press release, whether as a
result of new information, future developments or otherwise.
                                                                                
  Non-GAAP Financial Measures                                                   
                                                                                
This press release includes Non-GAAP Operating Expenses, a supplemental measure
of our performance that is not required by, or presented in accordance with,
U.S. GAAP and should not be considered as an alternative to operating expenses
or any other performance measure derived in accordance with GAAP.

We define Non-GAAP Operating Expenses as GAAP operating expenses excluding
stock-based compensation and fixed consideration related to in-licensing and
milestone payments.

We caution investors that amounts presented in accordance with our definition of
Non-GAAP Operating Expenses may not be comparable to similar measures disclosed
by our competitors because not all companies and analysts calculate this non-
GAAP financial measure in the same manner. We present this non-GAAP financial
measure because we consider it to be an important supplemental measure of our
performance and believe it is frequently used by securities analysts, investors,
and other interested parties in the evaluation of companies in our industry.
Management believes that investors’ understanding of our performance is enhanced
by including this non-GAAP financial measure as a reasonable basis for comparing
our ongoing results of operations.

Management uses this non-GAAP financial measure for planning purposes, including
the preparation of our internal annual operating budget and financial
projections; to evaluate the performance and effectiveness of our operational
strategies; and to evaluate our capacity to expand our business. This non-GAAP
financial measure has limitations as an analytical tool,
and should not be considered in isolation, or as an alternative to, or a
substitute for operating expenses or other financial statement data presented in
accordance with GAAP in our consolidated financial statements.

Rhythm has not provided a quantitative reconciliation of forecasted Non-GAAP
Operating Expenses to forecasted GAAP operating expenses because the Company is
unable, without making unreasonable efforts, to calculate the reconciling item,
stock-based compensation expenses, with confidence. This item, which could
materially affect the computation of forward-looking GAAP operating expenses, is
inherently uncertain and depends on various factors, some of which are outside
of Rhythm's control.

Corporate Contact:

David Connolly

Head of Investor Relations and Corporate Communications

Rhythm Pharmaceuticals, Inc.

857-264-4280

[email protected]
                                                                                
                          Rhythm Pharmaceuticals, Inc.                          
                                                                                
     Condensed Consolidated Statements of Operations and Comprehensive Loss     
                                                                                
                (in thousands, except share and per share data)                 
                                                                                
                                  (Unaudited)                                   
                                                                                
           Three                              Nine                              
           months                             months                            
           ended                              ended                             
           Septe…                             Septem…                           
           30,                                30,                               
  Reve…    2026               2025            2026               2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Prod…                                                                         
  reve…    $        92,128    $     51,298    $        223,4…    $     137,518  
  net                                                                           
  Lice…                  —               —                  —           -5,014  
  reve…                                                                         
  Total             92,128          51,298             223,4…          132,504  
  reve…                                                                         
  Costs                                                                         
  and                                                                           
  expe…                                                                         
  Cost                                                                          
  of                12,166           5,499             28,254           14,690  
  sales                                                                         
  Rese…                                                                         
  and               52,480          46,027             137,6…          125,307  
  deve…                                                                         
  Sell…                                                                         
  gene…             66,752          52,425             197,7…          137,460  
  and                                                                           
  admi…                                                                         
  Total                                                                         
  costs            131,398          103,9…             363,6…          277,457  
  and                                                                           
  expe…                                                                         
  Loss                                                                          
  from             -39,270          -52,6…             -140,…          -144,9…  
  oper…                                                                         
  Other                                                                         
  inco…                                                                         
  (exp…                                                                         
  Other                                                                         
  inco…               -157             274               -840            1,207  
  (exp…                                                                         
  net                                                                           
  Inte…             -4,495          -4,742             -13,6…          -15,968  
  expe…                                                                         
  Inte…              3,163           4,328              9,937           11,208  
  inco…                                                                         
  Total                                                                         
  other                                                                         
  inco…              -1489            -140             -4,521           -3,553  
  (exp…                                                                         
  net                                                                           
  Loss                                                                          
  befo…            -40,759          -52,7…             -144,…          -148,5…  
  inco…                                                                         
  taxes                                                                         
  Prov…                                                                         
  (ben…                                                                         
  for                  610             111              1,598              528  
  inco…                                                                         
  taxes                                                                         
  Net      $       -41,369    $     -52,9…    $        -146,…    $     -149,0…  
  loss                                                                          
  Accr…                                                                         
  divi…                                                                         
  on                  -984          -1,375             -3,153           -4,046  
  conv…                                                                         
  pref…                                                                         
  stock                                                                         
  Net                                                                           
  loss                                                                          
  attr…    $       -42,353    $     -54,2…    $        -149,…    $     -153,0…  
  to                                                                            
  comm…                                                                         
  stoc…                                                                         
  Net                                                                           
  loss                                                                          
  per                                                                           
  share                                                                         
  attr…                                                                         
  to       $         -0.61    $      -0.82    $         -2.18    $       -2.38  
  comm…                                                                         
  stoc…                                                                         
  basic                                                                         
  and                                                                           
  dilu…                                                                         
  Weig…                                                                         
  comm…                                                                         
  shar…                                                                         
  outs…            69,046…          66,26…             68,54…          64,346…  
  basic                                                                         
  and                                                                           
  dilu…                                                                         
  Net      $       -41,369    $     -54,2…    $        -146,…    $     -153,0…  
  loss                                                                          
  Other                                                                         
  comp…                                                                         
  inco…                                                                         
  (los…                                                                         
  Fore…                                                                         
  curr…                 77             834                870           -1,272  
  tran…                                                                         
  adju…                                                                         
  Unre…                                                                         
  gain                                                                          
  (los…                                                                         
  net      $          -909    $        488    $        -1,818              385  
  on                                                                            
  mark…                                                                         
  secu…                                                                         
  Comp…    $       -42,201    $     -52,9…    $        -147,…    $     -153,9…  
  loss                                                                          
                                                                                
                                                                                
                          Rhythm Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                (in thousands, except share and per share data)                 
                                                                                
                                  (Unaudited)                                   
                                                                                
  Assets                                                                        
  Current           September                      December                     
  assets:           30,2026                        31,2025                      
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash     $                    39,981    $                    54,301  
  equivalents                                                                   
  Short-term                            280,963                        334,648  
  investments                                                                   
  Accounts                                                                      
  receivable,                            39,120                         26,081  
  net                                                                           
  Inventory                              31,187                         25,753  
  Prepaid                                                                       
  expenses and                           28,111                         26,133  
  other current                                                                 
  assets                                                                        
  Total current                         419,362                        466,916  
  assets                                                                        
  Property and                              569                          1,104  
  equipment, net                                                                
  Right-of-use                            2,694                          3,049  
  asset                                                                         
  Intangible                             16,678                          5,319  
  assets, net                                                                   
  Restricted                              1,281                            522  
  cash                                                                          
  Other                                                                         
  long-term                               2,548                          3,286  
  assets                                                                        
  Total assets      $                   443,132    $                   480,196  
  Liabilities,                                                                  
  Convertible                                                                   
  Preferred                                                                     
  Stock                                                                         
  and                                                                           
  Stockholders’                                                                 
  equity                                                                        
  Current                                                                       
  liabilities:                                                                  
  Accounts          $                    10,687    $                    13,947  
  payable                                                                       
  Accrued                                                                       
  expenses and                          124,721                         83,855  
  other current                                                                 
  liabilities                                                                   
  Lease                                     731                            650  
  liability                                                                     
  Deferred                                    —                            194  
  revenue                                                                       
  Deferred                                                                      
  royalty                                14,751                          7,296  
  obligation,                                                                   
  current                                                                       
  Total current                         150,890                        105,942  
  liabilities                                                                   
  Long-term                                                                     
  liabilities:                                                                  
  Deferred                                                                      
  royalty                                87,915                        100,886  
  obligation                                                                    
  Lease                                                                         
  liability,                              2,784                          3,342  
  non-current                                                                   
  Total                                 241,589                        210,170  
  liabilities                                                                   
  Commitments                                                                   
  and                                                                           
  contingencies                                                                 
  (Note 14)                                                                     
  Series A                                                                      
  convertible                                                                   
  preferred                                                                     
  stock,                                                                        
  $0.001 par                                                                    
  value:                                                                        
  150,000 shares                                                                
  authorized;                                                                   
  115,000 and                                                                   
  132,500 shares                                                                
  issued and                                                                    
  outstanding at                                                                
  September 30,                         113,577                        130,957  
  2026 and                                                                      
  December 31,                                                                  
  2025,                                                                         
  respectively.                                                                 
  Liquidation                                                                   
  preference of                                                                 
  $116,725 and                                                                  
  $132,500 as                                                                   
  of September                                                                  
  30, 2026, and                                                                 
  December 31,                                                                  
  2025,                                                                         
  respectively.                                                                 
  Stockholders’                                                                 
  equity:                                                                       
  Preferred                                                                     
  stock, $0.001                                                                 
  par value:                                                                    
  9,850,000                                                                     
  shares                                                                        
  authorized; no                                                                
  shares                                      —                              —  
  issued and                                                                    
  outstanding at                                                                
  September 30,                                                                 
  2026 and                                                                      
  December 31,                                                                  
  2025                                                                          
  Common stock,                                                                 
  $0.001 par                                                                    
  value:                                                                        
  120,000,000                                                                   
  shares                                                                        
  authorized;                                                                   
  69,314,825 and                                                                
  67,205,321                                 70                             67  
  shares issued                                                                 
  and                                                                           
  outstanding at                                                                
  September 30,                                                                 
  2026                                                                          
  and December                                                                  
  31, 2025,                                                                     
  respectively                                                                  
  Additional                                                                    
  paid-in                             1,587,823                      1,491,675  
  capital                                                                       
  Accumulated                                                                   
  other                                  -1,744                           -796  
  comprehensive                                                                 
  loss                                                                          
  Accumulated                        -1,498,183                     -1,351,877  
  deficit                                                                       
  Total                                                                         
  stockholders’                          87,966                        139,069  
  equity                                                                        
  Total                                                                         
  liabilities,                                                                  
  convertible                                                                   
  preferred         $                   443,132    $                   480,196  
  stock and                                                                     
  stockholders’                                                                 
  equity                                                                        
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RYTM/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.